• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific enters aortic valve replacement space with $450 million Sadra Medical buyout

Boston Scientific enters aortic valve replacement space with $450 million Sadra Medical buyout

November 19, 2010 By MassDevice staff

BSX, Sadra logos

Boston Scientific Corp. (NYSE:BSX) agreed to acquire Sadra Medical Inc. in a deal worth $450 million.

The acquisition of Los Gatos, Calif.-based Sadra marks the medical device giant’s entry into the aortic valve replacement market. Sadra is developing a device, the Lotus valve system, that’s designed to replace the valve that can be deployed via catheter; Boston Scientific became a strategic investor in the company in 2005 and owns 14 percent of Sadra, according to a press release.

The deal calls for an upfront payment of $225 million ($193 million after the 14 percent stake is subtracted) and revenue- and regulatory-related milestone payments of up to $225 million more (which also net out at $1193 million).

Boston Scientific, flush from the $1.5 billion sale of its neurovascular business to Stryker Corp. (NYSE:SYK) last month, said it will pay for the Sadra deal with cash on hand.

"This acquisition represents another critical step in the execution of our strategy to realign Boston Scientific’s portfolio," BSX president and CEO Ray Elliott said in prepared remarks. "Sadra’s innovative technology is a natural fit with Boston Scientific’s core competencies in stents and catheter-based delivery systems, allowing us to leverage our clinical expertise and existing sales channels."

Boston Scientific has been a strategic investor in Sadra Medical since 2006, along with other backers Accuitive Medical Ventures, Finistere, Firstmark Capital, Oakwood, Onset Ventures, and SV Life Sciences. Sadra drummed up $30 million back May 2009.

Boston Scientific also announced CE Mark approval in the European Union for a trio of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, the Incepta, Energen and Punctua devices.

BSX shares were trading at $6.68 in mid-afternoon activity, up nearly 2 percent.

Filed Under: Business/Financial News, Mergers & Acquisitions, News Well, Replacement Heart Valves Tagged With: Boston Scientific, Sadra Medical Inc.

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy